![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body'... Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany. Show more
U.S. index futures are trading slightly higher in pre-market on Monday, amidst anticipation of the Fed’s decision on interest rates and Jerome Powell’s press conference, along with...
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2...
MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer...
In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were...
Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -0.778210116732 | 5.14 | 5.36 | 4.81 | 163215 | 5.0500433 | CS |
4 | -1.92 | -27.3504273504 | 7.02 | 7.11 | 4.8 | 175980 | 5.52468021 | CS |
12 | 0.03 | 0.591715976331 | 5.07 | 8.95 | 3.8 | 773295 | 6.98970502 | CS |
26 | -1.436 | -21.970624235 | 6.536 | 8.95 | 3.8 | 589390 | 6.52141191 | CS |
52 | -1.099 | -17.7286659139 | 6.199 | 8.95 | 2.235 | 698326 | 5.50927952 | CS |
156 | -61.4 | -92.3308270677 | 66.5 | 73.5 | 2.235 | 1160636 | 27.98508487 | CS |
260 | -26.5 | -83.8607594937 | 31.6 | 117.4 | 2.235 | 1241678 | 41.53225436 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions